Analytical Data
-
Gene name
SFRS5
- Application
-
Alternative Names
arginine/serine-rich 5; Delayed early protein HRS; Delayed-early protein HRS; HRS; Pre mRNA splicing factor SRP40; Pre-mRNA-splicing factor SRP40; Serine and arginine rich splicing factor 5; Serine/arginine-rich splicing factor 5; SFRS 5; SFRS5; Splicing factor; Splicing factor arginine/serine rich 5; SRP 40; SRP40; SRSF5; SRSF5_HUMAN
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q13243
-
Expression Region
1-181 aa
-
AA Sequence
MSGCRVFIGRLNPAAREKDVERFFKGYGRIRDIDLKRGFGFVEFEDPRDADDAVYELDGKELCSERVTIEHARARSRGGRGRGRYSDRFSSRRPRNDRRNAPPVRTENRLIVENLSSRVSWQDLKDFMRQAGEVTFADAHRPKLNEGVVEFASYGDLKNAIEKLSGKEINGRKIKLIEGSK
-
Molecular Weight
31.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SFRS5, also known as Splicing Factor, Arginine/Serine Rich 5, is a member of the serine/arginine-rich (SR) splicing factor family, which plays a crucial role in the regulation of pre-mRNA splicing and gene expression. Research has indicated that SFRS5 is involved in various cellular processes, including alternative splicing, RNA metabolism, and even translation. Abnormal expression of SFRS5 has been associated with several diseases, particularly cancer, where it may influence tumor progression and metastasis through modulation of splicing patterns. The study of SFRS5 is particularly significant as it provides insights into the complex regulatory networks governing gene expression and the potential for developing targeted therapies. Advances in molecular biology techniques, such as CRISPR/Cas9 and RNA-seq, have enabled researchers to elucidate the functional roles of SFRS5 in both normal and disease states. Additionally, understanding the mechanisms by which SFRS5 impacts splicing events offers valuable information for the development of biomarkers and therapeutic strategies aimed at diseases characterized by splicing dysregulation. As such, ongoing research into SFRS5 not only deepens our comprehension of fundamental cellular mechanisms but also opens avenues for innovative approaches in medical treatment and diagnostics.
